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Objectives: Alternative splicing and variable post-translational modiﬁcations result in proteoglycan 4
(PRG4) proteins with historically reported apparent molecular weights (Ma) ranging from 150 to
400 kDa. The objectives of this study were to (1) identify and determine the weight averaged molecular
weights (MW’s) of PRG4 proteins puriﬁed from mediumwith transforming growth factor-beta 1 (TGF-b1)
conditioned by mature bovine articular cartilage explants and (2) to examine the effect of reduction and
alkylation (RA) on PRG4.
Methods: Non-reduced (NR) and RA preparations of PRG4 were separated using high performance liquid
chromatography-size-exclusion chromatography with an in-line multi-angle laser light scattering
(MALLS) detector, which was used for absolute determination of PRG4 MW. Sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE), immunoblotting, and tandem mass spectrometry (MS/
MS) analysis were used to conﬁrm the identity of separated proteins.
Results: Three putative PRG4 monomers, one with previously uncharacterized MW, were identiﬁed in NR
and RA PRG4 preparations of 239 (223,255), 379 (369,389), and 467 (433,501) kDa. Additionallyw1 MDa
putative PRG4 dimer was identiﬁed. Release of a w90 kDa PRG4 fragment was also observed on SDS-
PAGE after RA. Western Blotting with anti-PRG4 antibodies detected immunoreactive bands with Ma
similar to MW for all species and excised bands were conﬁrmed to be PRG4 by MS/MS.
Conclusions: A variety of monomeric PRG4 proteins and a disulﬁde-bonded dimer/multimer are secreted
by chondrocytes in bovine cartilage explants. The observed decrease in MW’s of monomeric PRG4 species
upon RA may be due to the release of post-translationally cleaved fragments. Further study of these
species will provide insight into the PRG4 molecular structure and function relationship.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The proteoglycan 4 (PRG4) gene1 encodes for a family of mucin-
like proteins, including lubricin and superﬁcial zone protein (SZP).
These proteins are synthesized and secreted by cells within artic-
ular joints, including synoviocytes2 and superﬁcial zone articular
chondrocytes3, and are present in synovial ﬂuid (SF)4 and at the
surface of articular cartilage5. PRG4 acts as a boundary lubricant
in vitro on glass surfaces6e8 and at physiologically relevant
cartilage-on-cartilage interfaces9, singularly and synergistically
with hyaluronan (HA)10,11. Additionally, studies suggest that PRG4T.A. Schmidt, 2500 University
nada, T2N 1N4. Tel: 403-220-
ele), cecilia.alvarezveronesi@
calgary.ca (T.A. Schmidt).
s Research Society International. Por its fragments create a network of “entanglements” that are
responsible for increasing the relaxation time of SF, thereby
allowing strain energy induced by articular joint locomotion
to slowly dissipate, and for imparting chondroprotective properties
to SF12. Mutations to the PRG4 gene cause the autosomal-recessive
disorder camptodactyly-arthropathy-coxa vara-pericarditis (CACP),
which is characterized by pain, swelling, and restricted range
of motion in large joints and causes juvenile onset of non-
inﬂammatory joint failure13,14. Concurrently, PRG4 knockout mice
exhibit increased cartilage wear and higher friction in diarthrodial
joints than that observed inwild-type animals15. Reduction in PRG4
expression as seen after joint injury is associated with cartilage
degeneration and early onset of osteoarthritis (OA)16. Thus, PRG4 is
critical to the normal lubricating function of SF and to the main-
tenance of healthy joints.
The PRG4 gene contains 12 exons17 and encodes for a highly
conserved sequence of 1404 and 1445 amino acid protein inublished by Elsevier Ltd. All rights reserved.
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of w150 kDa for the unsubstituted core proteins5,18,19. PRG4
contains a central mucin-like domain, which is extensively gly-
cosylated with O-linked oligosaccharide substitutions that
account for greater than 50% of the mass of the expressed protein,
and contains globular, cysteine-rich domains at the N- and
C-termini. The core protein also contains attachment sites for
chondroitin and keratan sulfate chains2; however, it has been
shown that not all PRG4 molecules are substituted with these
glycosaminoglycans20. PRG4 has also been shown to form
disulﬁde-bonded multimers in normal SFs21, with intermolecular
bond formation believed to occur via the N-terminus of the
protein22,23. Reduction and alkylation (RA) of PRG4 reduces its
lubricating ability in vitro8,24 and also reduces its ability to bind to
cartilage surfaces8,22, indicating that multimerization of PRG4 is
a key structural component for biological function. Alternative
splicing of exons 2e5 of the PRG4 gene1,19,23,25e27 and variable
post-translational modiﬁcations have lead to the separate iden-
tiﬁcation of several homologous PRG4 species3,19,25. Transforming
growth factor-beta 1 (TGF-b1) has been shown to regulate alter-
native splicing of PRG4 by chondrocytes in cartilage explants
cultures23, as well as increase synthesis and secretion of
PRG419,28.
Initially isolated in 1977 from the lubricating protein fraction of
bovine SF, the protein was ﬁrst termed lubricating glycoprotein
(LGP-I)29 and then renamed “lubricin”30. The MW of lubricin was
determined to be 227.5 kDa by sedimentation-equilibrium
measurements31 and 206 kDa by Rayleigh light scattering30, but
exhibits an apparent migration on sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE) of 280 kDa6. In 1994,
Schumacher et al. described a “novel” proteoglycan, which was
synthesized and secreted exclusively by chondrocytes in the
superﬁcial zone of articular cartilage and was thus named SZP,
with an apparent molecular weight (Ma) of 345 kDa by SDS-PAGE2.
Due to differences in cellular origin2,3,5, in migration on SDS-
PAGE2,5,6 and in buoyant densities from sedimentation2,8, lubricin
and SZP were initially identiﬁed as distinct SF constituents.
However, cDNA sequencing and homology analysis revealed that
SZP and lubricin are both products of the megakaryocyte stimu-
lating factor (MSF) gene3,19,25, now referred to as the PRG4 gene1.
Initial cDNA cloning studies on the MSF gene were conducted by
Merberg et al. using the w25 kDa urinary MSF metabolite, which
was shown to be a partial peptide derived from a larger, glycosy-
lated precursor protein with a theoretical MW of 400 kDa17.
However, the exact biosynthetic pathways and molecular pro-
cessing that result in the production and secretion of diverse
protein products of the PRG4 gene, herein collectively referred to
as PRG4, are not well understood.
Multi-angle laser light scattering (MALLS) is a powerful tech-
nique that accurately determines molecular size and mass of
biomolecules in a non-destructive manner. Unlike traditional
methods for determining MW including size-exclusion chroma-
tography (SEC), gel electrophoresis, analytical ultracentrifugation
and time-of-ﬂight mass spectrometry, MALLS does not require the
use of relative standards, is relatively fast, and can be used to
characterize very high MW proteins and aggregates32,33. As such,
MALLS can conﬁrm the previously reported molecular weights Ma
of PRG4 species, whichmay have inherent inaccuracies when based
on SDS-PAGE due to the high extent of PRG4 glycosylation34.
Therefore, the objectives of this study were to (1) use high
performance liquid chromatography (HPLC)-SEC with in-line
MALLS to identify and determine the weight averaged MW’s of
PRG4 proteins puriﬁed from medium with TGF-b1 conditioned by
mature bovine cartilage explants and (2) to examine the effect of RA
on PRG4.Methods
Materials
Ethylenediaminetetraacetic acid (EDTA) and Tris-base were
purchased from Fisher Scientiﬁc (Fairlawn, NJ, USA), and bicin-
choninic acid assay (BCA) kit was purchased from Thermo Fisher
Scientiﬁc (Rockford, IL, USA). Sodium chloride, guanidine hydro-
chloride (GdHCl), and dithiothreitol (DTT) were purchased from
SigmaeAldrich (St. Louis, MO, USA). Sodium acetate was purchased
fromMP Biomedicals (Santa Ana, CA, USA), and iodoacetamide was
obtained from Acros Organics (Geel, Belgium). Diethylaminoethyl
(DEAE) Sepharose, ECL Prime Substrate, and polyvinylidene ﬂuo-
ride (PVDF) were purchased from GE Healthcare (Piscataway, NJ,
USA). Blotting grade non-fat milk and Tween-20 were obtained
from Bio-Rad Laboratories (Hercules, CA, USA). Unless otherwise
speciﬁed, all other gel andWestern Blotting reagents and apparatus
were purchased from Invitrogen (Carlsbad, CA, USA), as well as
cartilage culture media and reagents. Human, recombinant TGF-b1
was obtained from Peprotech (Rocky Hill, NJ, USA).
Anti-PRG4 polyclonal antibody LPN, which is speciﬁc to the
C-terminal sequence aa1356e1373 was purchased from Thermo
Fisher Scientiﬁc. Anti-sera Jl08N, raised against N-terminal
sequence aa75-95, was a gift from Dr. M. L. Warman (Harvard
Medical School, Boston, MA, USA). Goat anti-rabbit horseradish
peroxidase (HRP) coupled IgG was purchased from Chemicon
(Temecula, CA, USA).
PRG4 preparation & puriﬁcation
As described previously9,28, PRG4 was prepared from culture
media, supplemented with 10 ng/mL of TGF-b1, conditioned by
cartilage disks harvested from the patellofemoral groove of mature
bovine stiﬂe joints. PRG4 was puriﬁed from pooled media from the
4-week culture using anion exchange chromatography. Brieﬂy,
media was applied to a DEAE Sepharose column equilibrated with
0.15MNaCl, 0.005M EDTA, and 0.05M sodium acetate, pH¼ 6. The
columnwas washed with three volumes of 0.15 M NaCl buffer, then
eluted with a step gradient of 0.3 M and 0.615 M NaCl buffer. The
PRG4 enriched 0.615 M eluate and PRG4 containing 0.3 M eluate
were collected, concentrated, buffer exchanged into water with
a 30 kDa MW cutoff ﬁlter (Millipore; Billerica, MA, USA), and
quantiﬁed by BCA.
Reduction and alkylation of PRG4
Dried PRG4 was reconstituted in 4.0 M GdHCl, 50 mM Tris-base,
1 mM EDTA, pH ¼ 8.5 at a concentration of 2 mg/mL and incubated
with (RA) or without (non-reduced: NR) 10 mMDTT at 60C for 2 h,
followed by 40 mM iodoacetamide for 2 h in the dark at room
temperature. The samples were then stored at 20C or were
ethanol precipitated for SDS-PAGE analysis21. To assess if complete
reduction was occurring, samples were incubated with 10 mM DTT
for up to 5 h. Time points were taken every 30 mine1 h, and either
addition of alkylation reagent or ethanol precipitation was used to
stop the reaction. Extent of reduction was determined by exam-
ining the relative intensity of reduced product bands on SDS-PAGE.
HPLC-SEC-MALLS
NR and RA PRG4 species from the 0.615M eluatewere separated
using HPLC (Perkin Elmer-Series 200) with a size exclusion column
(WTC-050S5, 500Å pore size; Wyatt Technology Corp, Santa Bar-
bara, CA, USA) equilibrated in 4.0 M GdHCl and with in-line UV
(Perkin Elmer-Series 200), MALLS, and refractive index detectors
Fig. 1. HPLC-SEC-MALLS on PRG4. UV (e), RI (e e) and MALLS () traces from HPLC-
SEC of NR PRG4 (A). UV chromatograms for NR (e) and RA (e) PRG4 with peaks
analyzed for MW determination by MALLS numbered (B).
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Corp) for MW characterization. For each run, 250 mg of NR or RA
PRG4 were injected (n ¼ 3; with three technical repeats each) and
eluted with a ﬂow rate of 0.5 mL/min. UV, MALLS, and RI data were
collected and analyzed using ASTRA software (Wyatt Tech-
nology), and a dn/dc value of 0.160 mL/g was used for PRG430.
Calculated MW of the peaks are presented as mean with a 95%
conﬁdence interval (lower limit, upper limit), which was calculated
by multiplying the standard error of the mean by 1.96.
SDS-PAGE and Western Blotting
Two to 4 mg of PRG4 were resuspended in NuPAGE LDS sample
buffer and were heated at 70C for 10 min. The samples were
loaded onto a Novex 3e8% Tris-Acetate gel with 10 mL of HIMark
Pre-Stained High Molecular Weight Protein Standard. Electropho-
resis was conducted in NuPAGE Tris-Acetate SDS running buffer at
4C for 75min at 150 V in a vertical gel apparatus. Gels were stained
using Coomassie G-250 (SimplyBlue SafeStain) per manufacturer’s
instructions, or gels were electroblotted to 0.2 mm PVDF at
a constant current of 200 mA for 2hr in NuPAGE Transfer Buffer (0%
methanol). Membranes were blocked with 5% non-fat dry milk in
Tris-buffered saline with Tween (TBST) (20 mM Tris-base, 137 mM
NaCl, pH ¼ 7.6 with 0.1%(v/v) Tween-20) for 60 min at room
temperature and then incubated overnight at 4C with rocking
with 2 mg IgG/mL LPN primary antibody or 1:1000 J108N serum in
3% milk/TBST. Membranes were washed in TBST (3  10 min),
incubated in 0.5 mg/mL goat anti-rabbit HRP antibody in 3% milk/
TBST with rocking for 1hr at room temperature, and washed again
in TBST (3  10 min). To test for non-speciﬁc absorption of the
secondary antibody, blots were treated as described above, except
primary antibody was omitted for LPN or 1:1000 dilution of rabbit
serum was used in place of J108N. Immunoreactive bands were
detected using ECL Prime Chemiluminescent Substrate and CHEMI
Genius 2 Bio Imaging System (SYNGENE; Frederick, MD, USA).
MS/MS analysis
Stained protein bands of interest with Ma corresponding to
those determined for PRG4 species byMALLSwere excised from the
0.615 M lanes and submitted for identiﬁcation by tandem mass
spectrometry (MS/MS) to the Southern Alberta Mass Spectrometry
Centre (University of Calgary), as described previously21. For data
analysis, Mascot searches using MudPIT scoring with P < 0.05 were
conducted against bovine PRG4 sequences.
Results
HPLC-SEC-MALLS
HPLC-SEC was able to distinguish different MW species within
the 0.615 M PRG4 preparations, as indicated by representative,
normalized UV, MALLS, and RI chromatograms for NR PRG4
[Fig. 1(A)]. Three major peaks were observed in the UV trace for NR
and RA PRG4 [Fig. 1(B)]. After RA, the relative intensity of peak 1
decreased, while the relative intensities of peak 2 and peak 3
increased in the normalized UV trace [Fig. 1(B)]. The increase in
relative intensity for peak 2 is not readily observed in the ﬁgure,
due to normalization of the absorbance spectra to this peak.
Calculated MW of the peaks (n ¼ 3) are shown (Table I). For NR and
RA peak 1, the calculated Mw are not statistically different when
analyzed by an unpaired t-test, which may indicate incomplete
reduction of the PRG4 samples. Concurrently, a reduction time
course showed that a weak protein band with Ma corresponding to
w1 MDa on SDS-PAGE was present at an incubation time of 2 h anddid not completely disappear until after 4 h of incubation (data not
shown). The polydispersity (the ratio of the MW to the number
averaged molecular weight (MN)) was 1.03e1.05 for NR and RA
peaks 2e3 and was 1.2 for NR and RA peak 1.
SDS-PAGE and Western Blotting
Protein staining of the 0.3 M and 0.615 M NaCl eluates showed
bands with Ma consistent with the calculated MW from MALLS for
HPLC-SEC peaks 1e3 for NR [Fig. 2(A)] and peaks 2e3 for RA PRG4
[Fig. 2(C)]. At the given load (w2 mg of protein per lane) in Fig. 2,
a band corresponding to RA1 was not observed, however; when the
concentration of RA protein was increased four-fold, a band cor-
responding to RA1 was observed on SDS-PAGE with protein stain-
ing (data not shown). In addition, while only the 0.615MNaCl wash
was used for HPLC-SEC-MALLS, visualization of NR and RA peak 3
required analysis of the 0.3 M NaCl wash due to low apparent
abundance of these species on SDS-PAGE in the higher salt wash.
Western Blotting of the 0.3 and 0.615 M NaCl eluates showed LPN
immunoreactive reactive bands that co-migrated with NR1e3
[Fig. 2(B)] and J108N immunoreactive bands corresponding to RA
2,3 [Fig. 2(D)]. A band corresponding to NR3 was difﬁcult to detect
using LPN, therefore two 0.615 M blots [Fig. 2(B)] are shown to
illustrate immunoreactivity of this species. After RA, an
Maz90 kDa band appeared on SDS-PAGE and was J108N immu-
noreactive [Fig. 2 (C, D); F90].
Table I
Summary of SDS-PAGE, immunoreactivity, and MS/MS on PRG4 proteins. The calculated weight averaged MW’s from MALLS (Mw, n ¼ 3; with three technical repeats each)
for HPLC-SEC peaks 1e3 for NR and RA PRG4 are given with 95% conﬁdence intervals (lower limit, upper limit), along with a summary of SDS-PAGE, J108N and LPN bands
observed with apparent molecular weight, Ma, corresponding to a given Mw. Peptides identiﬁed from MS/MS of excised SDS-PAGE bands are also listed with their corre-
sponding starting amino acid sequence (bovine PRG4)
Western Blot SDS-PAGE
Molecular weight (Mw) (kDa) LPN J108N Protein Stain (Ma) MS/MS Peptide sequences bovine PRG4
NR 1 1180 (867, 1493) X X X 79RGRECDCDSDCKK
146KVIESEEITEEHSVSENQESSSSSSSSSSTIRK
1225RITEVWGIPSPIDTVFTRC
1315KQEPTQKC
1385RGLPNVVTSAISLPNIRK
1413KDQYYNIDVPSRT
NR 2 467 (433, 501) X X X X 91KYGKCCSDYGAFCEAVHNPTTPPPPKT
370KKPAPTTPKE
1225RITEVWGIPSPIDTVFTRC
1259RFTNDIKD
1385RGLPNVVTSAISLPNIRK
1413KDQYYNIDVPSRT
NR3 239 (223, 255) X X X 1385RGLPNVVTSAISLPNIRK
RA 1 1060 (890, 1230) X X 1225RITEVWGIPSPIDTVFTRC
1248KTFFKG
1253KGSQYWRF
1325RRPAINYSVYGETAQVRR
RA 2 379 (369, 389) X X X 685KEPAPTSPKEPAPTSPKE
RA 3 150 (108, 192) X X
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Bands with migrations corresponding to NR1e3 and RA 1e3
were excised from SDS-PAGE, trypsin digested, and submitted for
MS/MS analysis. Identiﬁed peptides were searched against the
bovine PRG4 sequences (Accession: DAA21008.1), and all bands
were conﬁrmed to be PRG4 except for RA3. The peptide matches for
each band with corresponding starting amino acid position are
listed in Table I.
Discussion
The results of this study demonstrate that chondrocytes in
articular cartilage explants predominately produce and secrete
three distinct PRG4 species, using SEC-MALLS. Two previously
uncharacterized PRG4 species with calculated weight averaged
MW’s ofw1MDa and 467 (403,501) kDawere identiﬁed, in addition
to a 239 (222,256) kDa species. The 467 kDa species is likely the fullFig. 2. SDS-PAGE and Western Blotting on PRG4. SDS-PAGE with Coomassie blue staining (
RA (C, D) PRG4 species on 0.3 M and 0.615 M NaCl eluates. Bands with Ma corresponding to
to be PRG4 by MS/MS, of w90 kDa after RA.length, glycosylated form of PRG4 previously identiﬁed as MSF
precursor17, but with a MW w70 kDa larger than predicted. Addi-
tionally, the calculated MW’s for RA2 and RA3 were determined to
be 379 (369,389) and 150 (108,192) kDa, respectively. After RA, the
relative abundance of the w1 MDa peak was signiﬁcantly dimin-
ished, with no statistical difference arising between the calculated
MW’s of 1.18 (0.906,1.493) and 1.06 (0.876,1.230) MDa for NR1 and
RA1, respectively, indicating that this species is a disulﬁde-bonded
PRG4 dimer or multimer. These results combined with a prelimi-
nary report from our laboratory35 are the ﬁrst to demonstrate that
bovine articular cartilage chondrocytes synthesize and secrete high
MW, disulﬁde-bonded multimers of PRG4.
A limitation of this study was the resolution of the SEC column,
which was designed for the separation of very large biomolecules
(w15 kDae5 MDa), as the MW’s of co-eluting species in each peak
are averaged together to calculate the MW during MALLS analysis.
Improved resolution of the multimer and monomer peaks could
potentially be achieved using a column with a larger pore size, butA, C) and Western Blot analysis with antibodies LPN (B) and J108N (D) of NR (A, B) and
Mw for a given peak are marked. F90 corresponds to the release of fragment, conﬁrmed
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achieving baseline resolution in the SEC separation, the PRG4 peaks
analyzed in this study had a polydispersity of w1 indicating that
the masses of the eluting species were fairly monodisperse. In
addition to the three main PRG4 peaks analyzed in both NR and RA
chromatograms, several small, poorly deﬁned peaks with MW’s less
than 100 kDawere observed, but elutedwith inconsistent retention
times thus precluding further analysis. These small peaks may be
contaminants remaining after DEAE puriﬁcation of conditioned
media (future studies could use a 100 kDa ﬁlter to reduce such
non-PRG4 contaminants). Additionally, reduction time course
experiments veriﬁed that RA of the peak 1, PRG4 multimer was
incomplete during the 2 h incubation period used in this study
(data not shown) and did not disappear until after 4 h, suggesting
that longer incubation times or increased concentration of reducing
agent should be used in future experiments. As PRG4 has a putative
HA binding domain17, samples were also treated with hyaluroni-
dase prior to RA and HPLC-SEC-MALLS, which did not signiﬁcantly
change the calculated Mw values (data not shown), indicating that
an interaction with any remaining HA in the preparation was not
occurring.
Some PRG4 species with high relative abundances in the SEC-UV
spectra were difﬁcult to detect using SDS-PAGE with protein
staining and immunoblotting. The negatively charged carbohy-
drates of glycoproteins have been shown to hinder the binding of
both Coomassie blue36 and silver ions37 during SDS-PAGE staining,
resulting in unreliable protein detection. Accordingly, densito-
metric analysis of the NR and RA 0.615 M, enriched PRG4 lanes did
not show signiﬁcant peaks corresponding to the 239 kDa and
150 kDa peaks observed in the UV traces (data not shown). As such,
the 0.15e0.3 M NaCl wash from the DEAE puriﬁcation, which has
a higher abundance of proteins with lower charge densities, was
probed in addition to the 0.3e0.615 M NaCl, PRG4 enriched wash
that was used in SEC-MALLS experiments. Due to poor transfer
efﬁciency and low concentration, a band with Ma corresponding to
RA1 was not observed with J108N immunoblotting and required
a four-fold increase in the amount of protein typically loaded for
visualization on SDS-PAGE with Coomassie blue staining (data not
shown). An immunoreactive band corresponding to NR3 was not
always detected, perhaps due to loss of proper conformation of the
binding epitope for LPN, which might be remedied by the use of
another anti-PRG4 antibody such as 6A1, a monoclonal antibody
(mAb) speciﬁc to the C-terminal of PRG4 that binds under NR and
RA conditions19. In a previous study, Western Blotting with mAb
6A1 under non-reducing conditions showed immunoreactive
bands at 140e150 and 60e70 kDa19, but these bands were not
typically observed in our NR preparations. Using J108N, PRG4
immunoreactive bands atw150 kDa were intermittently observed
after RA in the 0.3 M and 0.615 Mwashes. Excised SDS-PAGE bands
with Ma corresponding to each calculated MW from MALLS were
submitted for MS/MS analysis, which conﬁrmed that NR1e3 and
RA1e2 were indeed PRG4. However, a bandwithMa corresponding
to RA3 could not be positively identiﬁed as PRG4 byMS/MS; thus, it
remains to be determined whether the 150 kDa, RA3 peak with
a MW similar to that of the PRG4 core protein is in fact a partial,
glycosylated or unglycosylated PRG4 product or an impurity
present in this preparation. Additionally, MS/MS analysis on
the 60 kDa band [0.3 M, Fig. 2 (C)] did not display any peptide
matches to PRG4, and analysis of the Maz 460 kDa, reduced band
[0.615 M, Fig. 2 (C)] matched to PRG4 sequences 146KVIESEEITEE
HSVSENQESSSSSSSSSSTIRK, 370KKPAPTTPKE, 1225RITEVWGIPSPID
TVFTRC, and 1259RFTNDIKD.
The results of this study agree with and extend previous studies
on the molecular organization of PRG4. The reported MW’s in this
study correspond with historically reported masses for lubricin31(NR3) and SZP2,5 (RA2). Additionally, the identiﬁcation of
w1 MDa PRG4 protein supports the ﬁndings of a previous study in
which disulﬁde-bonded dimers were isolated from normal bovine
SF21. Furthermore, RA of PRG4 was hypothesized to result in the
collapse of disulﬁde-bonded multimers into one or two easily
identiﬁable PRG4 monomer(s) and/or fragment(s). However, after
RA rather than only observing a shift in the relative intensities for
NR and RA peaks 1e3, a decrease in MW of w90 kDa occurred
between NR2 and RA2 and between NR3 and RA3. The release of
low Ma fragments upon reduction of PRG4 was observed using
SDS-PAGE and Western Blotting (F90, Fig. 2), including a Ma
w90 kDa J108N immunoreactive band, which may or may not
correspond to the observed shift in MW. While MS/MS analysis of
F90 only matched to the human PRG4 sequence (1029KKPSTKKPKT-
human similar to 1071KKPSTKKPRT-bovine), the fragment release is
consistent with a previous report where an w70 kDa fragment,
conﬁrmed to be PRG4 by MS/MS, was released after RA and was
speculated to be a truncated and/or under glycosylated PRG4
species21. In another study, the formation of a w90 kDa band on
SDS-PAGE in reduced samples of PRG4 was observed, along with
w50 andw28 kDa fragments that were believed to be breakdown
products due to sample heating6. As such, future studies in which
RA of PRG4 preparations of isolated NR1 and NR2 species are
examined may provide more information on fragment release and
help clarify the mechanisms of PRG4 assembly and processing.
Other studies using mouse and human recombinant constructs
of PRG4 have demonstrated release upon RA of a 12e14 kDa PRG4
fragment that is a C-terminal peptide generated from post-
translational subtilisin-like proprotein convertase (SPC) cleavage
that remains disulﬁde-bonded to the main protein chain of the
C-terminal globular domain22,38. Mutations to either the conserved
arginine cleavage site (RFERA) or to one of two cysteines respon-
sible for the intra-chain disulﬁde bond prevents SPC mediated
cleavage. Cleavage is predicted to induce a normal structural
conformation that is critical to the function of PRG4 in SF, which is
supported by the detection of immunoreactive SPC fragments of
PRG4 in healthy porcine and bovine SF and by the identiﬁcation of
a mutation to PRG4 in a subset of patients with CACP that prevents
SPC cleavage38. As such, the shift in PRG4 MW after reduction
observed in this study may also represent the loss of several
disulﬁde-bonded fragments that are formed from SPC mediated
cleavage in combination with additional, uncharacterized pro-
cessing events on the termini of PRG4 or in combination with
partial degradation of PRG4 by other proteases. PRG4 has been
shown to be susceptible to degradation by matrix metallo-, serine,
and cysteine proteases39,40. The release of multiple fragments is
supported by the appearance of several low Ma, J108N immuno-
reactive fragments on SDS-PAGE after reduction of PRG4. However,
an immunoreactive band corresponding to the release of the SPC
cleavage fragment was not detected, as it would migrate with the
front in the gel system employed in this study, which is optimized
for the detection of high MW proteins (w31e460 kDa).
TGF-b1 was used here to increase synthesis and secretion of
PRG4 by chondrocytes in explant culture19,28. While TGF-b1 has
been shown to increase synthesis of an isoform lacking exons 4 and
5 and to decrease expression of the full length isoform23, the
change in MW based on the primary amino acid sequences between
the smallest and largest predicted PRG4 isoforms would be only
w20 kDa. Thus, alternative splicing alone is not enough to explain
the differences in the observed MW’s of secreted PRG4 products. In
all known PRG4 isoforms, themucin-like domain that is encoded by
exon 6 is conserved; therefore, differences in PRG4 MW are most
likely due to differences in O-glycosylation and in glycosamino-
glycan substitution of the core protein. In a previous study, treat-
ment of human PRG4 with Ma w350 kDa with sialidase caused
B.L. Steele et al. / Osteoarthritis and Cartilage 21 (2013) 498e504 503a decrease of w70 kDa in mass, and further treatment with
O-glycanase resulted in two PRG4 proteins with Ma of w225 and
w250 kDa on SDS-PAGE. Yet, a plausible explanation for the pres-
ence of two isoforms, both of which have Ma greater than predicted
for the PRG4 core, is that incomplete deglycosylation of PRG4 may
have occurred41. Another study showed that deglycosylation of
human PRG4 with Ma ofw280 kDa resulted in a 120 kDa product,
but the extent of deglycosylation was not known3. Since deglyco-
sylation results in diminished lubricating ability of PRG47 and since
changes in the extent of PRG4 glycosylation have been detected in
different disease states41, glycosylation is a critical structural
component to the biological function of PRG4. As the level of TGF-
b1 used in the culture media is within the range observed to occur
in arthritic human SF42, the distribution of secreted MW species
observed in this study may represent a pathophysiological state.
Therefore, future studies that evaluate the effect of TGF-b1 stimu-
lation of cultured articular cartilage on the MW of secreted PRG4
and of its reduction products to those observed in the absence of
growth factor may clarify differences in PRG4 synthesis and
proteolysis between healthy and diseased states.
In conclusion, the results presented in this study illustrate that
the biosynthetic pathways leading to the secretion of PRG4 species
with varying MW’s are complex and involve alternative splicing,
glycosylation, post-translational cleavage, and potentially proteo-
lytic activation/degradation. The methods developed here allow for
the separation and accurate characterization of PRG4 species with
differing molecular masses. Further study of these species will
provide insight into the PRG4 molecular structure and function
relationship through examination of their, potentially differential,
ability to bind to physiologically relevant surfaces and provide
boundary lubrication, and/or to contribute to the formation of
“entanglement” networks in SF that dissipate strain energy. In
addition, studies examining chondroitinase and keratanase treat-
ment and/or deglycosylation may also provide new insights into
the functional roles of these modiﬁcations on the different PRG4
species. Collectively, these results could contribute to the under-
standing of the roles of these different PRG4 species in normal and
pathological SF and, ultimately, in possible OA biotherapeutic
strategies involving PRG443,44.
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